This transcript has been edited for clarity. Kenneth Pienta, MD: Hi. I am Dr. Ken Pienta, and I'm joined by my nurse practitioner colleague, Diane Reyes-Dagher, for this CareCues conversation on how ...

Researchers on a phase 1/2 trial provided the first dose of gotistobart plus Pluvicto to a specific patient population with prostate cancer. The first patient has been dosed in a phase 1/2 trial ...

A 68-year-old man presented to the emergency department with haematuria and penile pain. His medical history included benign prostatic hyperplasia, but no follow-up examinations had been performed.

The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...

Growing evidence indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later ...

A cross-sectional survey of patient preferences found that the out-of-pocket cost of treatment was the most impactful attribute for patients when choosing an androgen deprivation therapy (ADTs) for ...

For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track ...

AI could eliminate the "postcode lottery" surrounding a life-extending treatment for advanced prostate cancer, researchers have said. A recent study found that AI can identify patients who will ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early ...